FCCC LOGO Faculty Publications
Choueiri TK , Atkins MB , Bakouny Z , Carlo MI , Drake CG , Jonasch E , Kapur P , Lewis B , Linehan WM , Mitchell MJ , Pal SK , Pels K , Poteat S , Rathmell WK , Rini BI , Signoretti S , Tannir N , Uzzo R , Wood CG , Hammers HJ
Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
J Natl Cancer Inst. 2021 Mar 1;113(3) :234-243
PMID: 32359162    PMCID: PMC7936057    URL: https://www.ncbi.nlm.nih.gov/pubmed/32359162
Back to previous list
Abstract
Kidney cancer is one of the ten most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma (RCC) launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.
Notes
1460-2105 Choueiri, Toni K Atkins, Michael B Bakouny, Ziad Carlo, Maria I Drake, Charles G Jonasch, Eric Kapur, Payal Lewis, Bryan Linehan, W Marston Mitchell, Michael J Pal, Sumanta K Pels, Kevin Poteat, Susan Rathmell, W Kimryn Rini, Brian I Signoretti, Sabina Tannir, Nizar Uzzo, Robert Wood, Christopher G Hammers, Hans J Journal Article United States J Natl Cancer Inst. 2020 May 2. pii: 5828225. doi: 10.1093/jnci/djaa064.